Core Viewpoint - Aoyou has established a complete probiotic ecosystem covering strain research, intelligent production, and end products through strategic mergers and acquisitions, self-built factories, technological innovation, and industry-university-research collaboration, positioning itself as a leading enterprise in China's probiotic industry [1][2][12] Industry Overview - The probiotic industry in China has experienced rapid growth driven by policy support, scientific breakthroughs, and market demand, with an annual growth rate of 11%-12% and an expected market size exceeding 130 billion yuan by 2025 [2][4] Strategic Mergers and Acquisitions - Aoyou's global layout of probiotic business was achieved through a "three-step" strategy, including the acquisition of Nutrition Care in 2016, which integrated 47 years of industry experience, and the acquisition of Fenghua Biotechnology in 2019, rebranding it as "Jinqi Biological" [4][6] Technological Innovation and Strain Development - Aoyou has made significant advancements in strain research, with the MP108 strain becoming the first domestically developed infant probiotic strain approved by the National Health Commission in 2021, breaking the technological monopoly of Western countries [6][8] - The CP-9 strain received GRAS certification from the FDA in 2025, marking another international recognition for Chinese probiotic strains [6][8] Research and Development Network - Aoyou has established a global R&D network with a "1+6+N" model, ensuring diversity in strain selection and product adaptability to Chinese consumers [8] Brand Matrix and Market Positioning - Aoyou has created a dual-brand matrix with Jinqi Biological and NC, targeting both adult and child consumer groups, facilitating a seamless connection from production to consumption [9][11] Product Innovation and Application - Aoyou's strategic collaboration with Jiangnan University has led to the development of innovative probiotic products, such as the sleep probiotic leveraging endogenous GABA technology, expanding the application boundaries of probiotics [11][12]

Core Insights - The 8th China International Import Expo (CIIE) was held from November 5 to 10, showcasing 4,108 companies from 155 countries and regions, emphasizing China's commitment to high-level opening-up with the theme "New Era, Shared Future" [1] - Dairy companies are shifting their competition focus from traditional supply chains to technological research and precise nutrition, particularly targeting infant and elderly markets with functional product upgrades [2][3] Group 1: Innovation and Product Development - Dairy companies are increasingly investing in R&D to meet the specific nutritional needs of different age groups, with products like Nutrition Care's new probiotics for children and adults, and Aoyou's high-calcium goat milk powder for the elderly [2][3] - The infant nutrition market is seeing significant innovation, with companies like a2 Milk and Nestlé's Wyeth launching advanced formula products that incorporate Human Milk Oligosaccharides (HMO), reflecting a technological leap in infant formula [2][3] Group 2: Market Dynamics and Consumer Trends - The demand for infant formula in China has surpassed 200 billion yuan, with high-end functional products experiencing a compound annual growth rate of over 15% [3] - The aging population in China, with over 280 million people aged 60 and above, is driving the demand for health management products focused on bone health, cognitive function, and gut regulation [3] Group 3: Globalization and Industry Collaboration - Chinese dairy companies are actively pursuing global supply chain integration, with companies like Yili and Aoyou emphasizing the importance of international collaboration and innovation to enhance their global presence [5][6][7] - Aoyou has established a supply chain in key dairy-producing countries and operates 11 factories globally, aiming to meet the rising global demand for nutritional health products [7]